Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

by · The Cerbat Gem

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 112,400 shares, a drop of 82.8% from the September 15th total of 652,500 shares. Currently, 6.4% of the shares of the company are sold short. Based on an average trading volume of 806,900 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their price target on Monopar Therapeutics from $2.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

Read Our Latest Stock Report on MNPR

Monopar Therapeutics Stock Performance

Shares of NASDAQ:MNPR traded up $0.09 during trading on Thursday, reaching $5.17. The company had a trading volume of 44,151 shares, compared to its average volume of 623,527. Monopar Therapeutics has a twelve month low of $1.37 and a twelve month high of $8.65. The firm has a market capitalization of $90.39 million, a PE ratio of -9.77 and a beta of 1.26. The firm’s fifty day moving average is $3.44 and its 200 day moving average is $3.49.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Equities analysts predict that Monopar Therapeutics will post -1.93 earnings per share for the current fiscal year.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Featured Stories